Zealand Pharma Crecimiento futuro

Future controles de criterios 5/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Zealand Pharma de 97% y 41.2% respectivamente, mientras que el BPA crecerá en un 103.9% al año.

Información clave

97.0%

Tasa de crecimiento de los beneficios

103.9%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	31.3%
Tasa de crecimiento de los ingresos	41.2%
Rentabilidad financiera futura	n/a
Cobertura de analistas	Good
Última actualización	n/a

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Previsiones de crecimiento de beneficios e ingresos

DB:22ZA - Estimaciones futuras de los analistas y datos financieros pasados (DKK Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2024	681	131	125	-96	5
12/31/2023	972	474	362	10	6
12/31/2022	132	-897	-790	-767	6
9/30/2022	278	-1,118	-999	-978	N/A
6/30/2022	288	-1,108	-1,083	-1,060	N/A
3/31/2022	302	-957	-1,182	-1,161	N/A
12/31/2021	293	-1,018	-1,234	-1,212	N/A
9/30/2021	158	-925	-1,183	-1,181	N/A
6/30/2021	161	-1,012	-1,085	-1,071	N/A
3/31/2021	347	-909	-870	-844	N/A
12/31/2020	353	-847	-714	-689	N/A
9/30/2020	301	-660	-618	-580	N/A
6/30/2020	255	-545	-670	-632	N/A
3/31/2020	54	-624	-698	-671	N/A
12/31/2019	41	-572	-433	-409	N/A
9/30/2019	43	-508	-408	-391	N/A
6/30/2019	33	524	927	-346	N/A
3/31/2019	28	551	952	-320	N/A
12/31/2018	38	581	810	-461	N/A
9/30/2018	35	601	853	-417	N/A
6/30/2018	74	-361	-317	-310	N/A
3/31/2018	68	-346	-326	-320	N/A
12/31/2017	136	-274	-286	-279	N/A
9/30/2017	306	-112	-69	-64	N/A
6/30/2017	307	-100	-116	-113	N/A
3/31/2017	306	-102	-57	-52	N/A
12/31/2016	231	-157	38	41	N/A
9/30/2016	221	-138	-116	-114	N/A
6/30/2016	189	-158	N/A	-128	N/A
3/31/2016	188	-139	N/A	-120	N/A
12/31/2015	188	-114	N/A	-225	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que 22ZA sea rentable en los próximos 3 años, lo que se considera un crecimiento más rápido que la tasa de ahorro (0.03%).

Beneficios vs. Mercado: Se prevé que 22ZA sea rentable en los próximos 3 años, lo que se considera un crecimiento del mercado superior a la media.

Beneficios de alto crecimiento: Se espera que 22ZA sea rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (41.2% al año) de 22ZA crezcan más rápidamente que los del mercado German (5.2% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos (41.2% al año) de 22ZA crezcan más rápidamente que un 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de 22ZA se prevé que sea elevada dentro de 3 años.

Zealand Pharma Crecimiento futuro

Future controles de criterios 5/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Zealand Pharma A/S Revises Revenue Guidance for the Full Year of 2022

Zealand Pharma A/S Reaffirms Earnings Guidance for the Full Year of 2021

Recent updates

Zealand Pharma A/S Approves Appointments to the Board

Zealand Pharma A/S Announces Board Changes

Zealand Pharma A/S Announces Boehringer Ingelheim Survodutide Phase 2 Trial Shows 83% of Adults Treated a Statistically Significant Improvement of Metabolic Dysfunction-Associated Steatohepatitis

Zealand Pharma A/S, Annual General Meeting, Mar 20, 2024

Zealand Pharma A/S has completed a Follow-on Equity Offering in the amount of DKK 1.45362 billion.

Zealand Pharma A/S has filed a Follow-on Equity Offering in the amount of DKK 1.45362 billion.

Zealand Pharma A/S Appoints Enrique Conterno and Elaine Sullivan as Board Observers

Zealand Pharma A/S to Report Q1, 2024 Results on May 16, 2024

Boehringer Ingelheim and Zealand Pharma A/S Announces Initiation of Three Phase III Trials

Zealand Pharma A/S Announces Designation of Priority Review by the US FDA for Dasiglucagon in Congital Hyperinsulinism

Zealand Pharma A/S Announces Positive Results from Part 1 of Multiple Ascending Dosing Trial with Amylin Analog ZP8396

Zealand Pharma Submits Marketing Authorization Application for Dasiglucagon for Treatment of Severe Hypoglycemia in Diabetes to the European Medicines Agency

Boehringer Ingelheim and Zealand Pharma A/S Announces Phase II Trial Showed 14.9% Weight Loss in People Living with Obesity or Unveil

Zealand Pharma A/S has completed a Follow-on Equity Offering in the amount of DKK 786.05 million.

Zealand Pharma A/S Announces Positive Results from Phase 3 Trial of Glepaglutide in Patients with Short Bowel Syndrome (Ease 1)

Zealand Pharma Presents Data from Phase 3 Trial of Dasiglucagon in Congenital Hyperinsulinism At the 60Th Annual Espe Meeting

Zealand Pharma A/S Announces Chief Financial Officer Changes

Zealand Pharma A/S Revises Revenue Guidance for the Full Year of 2022

Zealand Pharma Announces Voluntary Delisting of American Depositary Shares from the Nasdaq Global Select Market

Zealand Pharma A/S Presents Data from Phase 1 Trial of Dapiglutide and to Move into Phase 2 Trial for Obesity

Zealand Pharma Announces Appoints David M. Kendall, as Chief Medical Officer

Zealand Pharma A/S Announces Positive Top-Line Results from Its Second Phase 3 Clinical Trial of Dasiglucagon in Pediatric Patients with Congenital Hyperinsulinism

Zealand Pharma A/S (CPSE:ZEAL) entered into an agreement to acquire V-Go® Insulin Delivery Device from Zealand Pharma for $10 million.

Zealand Pharma Announces CEO Changes

Zealand Pharma A/S Announces Completion of Patient Enrollment in the Second Phase 3-Trial, 17103 in Children with Congenital Hyperinsulinism

Zealand Pharma Completes Enrollment in Ease-SBS 1 Phase 3 Trial Assessing Glepaglutide in Patients with Short Bowel Syndrome

Zealand Pharma Announces Enrollment of Last Patient Needed for Interim Analysis of EASE-SBS 1 Phase 3 Trial Assessing Glepaglutide in Patients with Short Bowel Syndrome

Zealand Pharma A/S announced that it expects to receive $200 million in funding from Oberland Capital Management LLC

Zealand Pharma Announces Successful Outcome of Phase 1B Clinical Trial with GLP1-GLP2 Dual Receptor Agonist, Dapiglutide

Zealand Pharma A/S Presents Data At 2021 ESPEN Virtual Congress Demonstrating Dose-Dependent Effects of Glepaglutide in Both Small and Large Intestines of Animal Models –in Contrast to Short-Acting GLP-2

Zealand Pharma Announces First Patient Dosed in EASE-SBS 4 Phase 3b Trial Assessing Glepaglutide in Patients with Short Bowel Syndrome

Protagonist Therapeutics, Inc Announces Resolution of Contract Dispute with Zealand Pharma

Zealand Pharma Announces U.S. Commercial Availability of Zegalogue (Dasiglucagon) Injection

Boehringer Ingelheim and Zealand Pharma Receive FDA Fast Track Designation for Investigational Treatment for NASH

Zealand Pharma A/S Receives First FDA Approval and Prepares for Launch of Zegalogue® (Dasiglucagon) Injection

Zealand Pharma A/S Reaffirms Earnings Guidance for the Full Year of 2021

Zealand Pharma A/S Announces Publication of Phase 3 Trial Evaluating Efficacy and Safety of Dasiglucagon for Treatment of Severe Hypoglycemia in Adult Patients with Diabetes

Zealand Pharma A/S Announces Data from the First Phase 3-Trial with Dasiglucagon in Congenital Hyperinsulinism (Chi)

Zealand Pharma A/S to Report Q3, 2021 Results on Nov 11, 2021

Zealand Pharma Continues to Advance Clinical Programs and Commercial Launch Capabilities

Zealand Pharma A/S (CPSE:ZEAL) completed the acquisition of substantially all assets of Valeritas Holdings, Inc.

Previsiones de crecimiento de beneficios e ingresos

Previsiones de crecimiento futuro de los analistas

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

Descubre empresas en crecimiento